Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy.
Journal: The oncologist
Published: March 02, 2026
Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma.
Journal: bioRxiv : the preprint server for biology
Published: July 15, 2025
Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.
Journal: Nature communications
Published: December 17, 2024
Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer.
Journal: The oncologist
Published: December 08, 2024
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.
Journal: The Lancet. Digital health
Published: October 01, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Journal: Cancer biomarkers : section A of Disease markers
Published: September 13, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.
Journal: Oncology
Published: June 26, 2024
Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.
Journal: Journal of gastrointestinal oncology
Published: April 19, 2024
Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB.
Journal: ESMO gastrointestinal oncology
Published: March 21, 2024
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Journal: Journal of immunotherapy and precision oncology
Published: February 14, 2024
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: December 13, 2023
Last Updated: 09/26/2026